The US Food and Drug Administration has also started to recognize the potential of these drugs: in 2018, they designated certain psychedelic treatments with a “breakthrough therapy” status, which means that it has therapeutic potential. Several renowned medical schools and hospitals around the United States have also opened psychedelic medicine departments which have been entirely devoted to studying the impact of psilocybin and LSD.